BACKGROUND: HIV-infected women need access to safe contraception. We hypothesized that women using depomedroxyprogesterone acetate (DMPA) contraception would have faster HIV disease progression than women using oral contraceptive pills (OCPs) and nonhormonal methods. METHODS: In a previously reported trial, we randomized 599 HIV-infected women to the intrauterine device (IUD) or hormonal contraception. Women randomized to hormonal contraception chose between OCPs and DMPA. This analysis investigates the relationship between exposure to hormonal contraception and HIV disease progression [defined as death, becoming eligible for antiretroviral therapy (ART), or both]. RESULTS: Of the 595 women not on ART at the time of randomization, 302 were allocated to hormonal contraception, of whom 190 (63%) initiatedDMPA and 112 (37%) initiated OCPs. Women starting IUD, OCPs, or DMPA were similar at baseline. Compared with women using the IUD, the adjusted hazard of death was not significantly increased among women using OCPs [1.24; 95% confidence interval (CI) 0.42-3.63] or DMPA (1.83; 95% CI 0.82-4.08). However, women using OCPs (adjusted hazard ratio (AHR) 1.69; 95% CI 1.09-2.64) or DMPA (AHR 1.56; 95% CI 1.08-2.26) trended toward an increased likelihood of becoming eligible for ART. Women exposed to OCPs (AHR 1.67; 95% CI 1.10-2.51) and DMPA (AHR 1.62; 95% CI 1.16-2.28) also had an increased hazard of meeting our composite disease progression outcome (death or becoming ART eligible) than women using the IUD. CONCLUSION: In this secondary analysis, exposure to OCPs or DMPA was associated with HIV disease progression among women not yet on ART. This finding, if confirmed elsewhere, would have global implications and requires urgent further investigation.
RCT Entities:
BACKGROUND:HIV-infectedwomen need access to safe contraception. We hypothesized that women using depomedroxyprogesterone acetate (DMPA) contraception would have faster HIV disease progression than women using oral contraceptive pills (OCPs) and nonhormonal methods. METHODS: In a previously reported trial, we randomized 599 HIV-infectedwomen to the intrauterine device (IUD) or hormonal contraception. Women randomized to hormonal contraception chose between OCPs and DMPA. This analysis investigates the relationship between exposure to hormonal contraception and HIV disease progression [defined as death, becoming eligible for antiretroviral therapy (ART), or both]. RESULTS: Of the 595 women not on ART at the time of randomization, 302 were allocated to hormonal contraception, of whom 190 (63%) initiated DMPA and 112 (37%) initiated OCPs. Women starting IUD, OCPs, or DMPA were similar at baseline. Compared with women using the IUD, the adjusted hazard of death was not significantly increased among women using OCPs [1.24; 95% confidence interval (CI) 0.42-3.63] or DMPA (1.83; 95% CI 0.82-4.08). However, women using OCPs (adjusted hazard ratio (AHR) 1.69; 95% CI 1.09-2.64) or DMPA (AHR 1.56; 95% CI 1.08-2.26) trended toward an increased likelihood of becoming eligible for ART. Women exposed to OCPs (AHR 1.67; 95% CI 1.10-2.51) and DMPA (AHR 1.62; 95% CI 1.16-2.28) also had an increased hazard of meeting our composite disease progression outcome (death or becoming ART eligible) than women using the IUD. CONCLUSION: In this secondary analysis, exposure to OCPs or DMPA was associated with HIV disease progression among women not yet on ART. This finding, if confirmed elsewhere, would have global implications and requires urgent further investigation.
Authors: Jared M Baeten; Ludo Lavreys; Manish Sagar; Joan K Kreiss; Barbra A Richardson; Bhavna Chohan; Dana Panteleeff; Kishorchandra Mandaliya; Jeckoniah O Ndinya-Achola; Julie Overbaugh; Tim Farley; Christina Mwachari; Craig Cohen; Tsungai Chipato; Unop Jaisamrarn; Orawan Kiriwat; Ann Duerr Journal: J Acquir Immune Defic Syndr Date: 2005-03 Impact factor: 3.731
Authors: Jason M Brenchley; Nitin J Karandikar; Michael R Betts; David R Ambrozak; Brenna J Hill; Laura E Crotty; Joseph P Casazza; Janaki Kuruppu; Stephen A Migueles; Mark Connors; Mario Roederer; Daniel C Douek; Richard A Koup Journal: Blood Date: 2002-11-14 Impact factor: 22.113
Authors: L Danel; C Vincent; F Rousset; B Klein; R Bataille; M Flacher; B G Durie; J P Revillard Journal: J Steroid Biochem Date: 1988 Impact factor: 4.292
Authors: Ludo Lavreys; Jared M Baeten; Varsha Chohan; R Scott McClelland; Wisal M Hassan; Barbra A Richardson; Kishorchandra Mandaliya; Jeckoniah O Ndinya-Achola; Julie Overbaugh Journal: Clin Infect Dis Date: 2006-03-27 Impact factor: 9.079
Authors: Helen E Cejtin; Lisa Jacobson; Gayle Springer; D Heather Watts; Alexandra Levine; Ruth Greenblatt; Kathryn Anastos; Howard L Minkoff; Leslie S Massad; Julie B Schmidt Journal: AIDS Date: 2003-07-25 Impact factor: 4.177
Authors: P A Marx; A I Spira; A Gettie; P J Dailey; R S Veazey; A A Lackner; C J Mahoney; C J Miller; L E Claypool; D D Ho; N J Alexander Journal: Nat Med Date: 1996-10 Impact factor: 53.440
Authors: Chelsea B Polis; Maria J Wawer; Noah Kiwanuka; Oliver Laeyendecker; Joseph Kagaayi; Tom Lutalo; Fred Nalugoda; Godfrey Kigozi; David Serwadda; Ronald H Gray Journal: AIDS Date: 2010-07-31 Impact factor: 4.177
Authors: Charles S Morrison; Pai-Lien Chen; Immaculate Nankya; Anne Rinaldi; Barbara Van Der Pol; Yun-Rong Ma; Tsungai Chipato; Roy Mugerwa; Megan Dunbar; Eric Arts; Robert A Salata Journal: J Acquir Immune Defic Syndr Date: 2011-06-01 Impact factor: 3.731
Authors: Catherine S Todd; Tracy C Anderman; Sarah Long; Landon Myer; Linda-Gail Bekker; Gregory A Petro; Heidi E Jones Journal: Contraception Date: 2018-02-09 Impact factor: 3.375
Authors: Kimberly K Scarsi; Kristin M Darin; Catherine A Chappell; Stephanie M Nitz; Mohammed Lamorde Journal: Drug Saf Date: 2016-11 Impact factor: 5.606
Authors: J Saxton; R Malyuta; I Semenenko; T Pilipenko; R Tereshenko; E Kulakovskaya; I Adejnova; L Kvasha; C Thorne Journal: Hum Reprod Date: 2010-07-19 Impact factor: 6.918